Nucleic Acid Pathogen Testing - Cigna
This Coverage Policy (CP) addresses nucleic acid infectious pathogen testing. Infectious pathogen testing using nucleic acid laboratory methods identifies the deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) of disease-causing microorganisms, including viruses, bacteria and fungi, including yeast, for the purpose of diagnosis and treatment.
Download Nucleic Acid Pathogen Testing - Cigna
Information
Domain:
Source:
Link to this page:
Documents from same domain
Molecular Diagnostic Testing for Hematology and Oncology ...
static.cigna.comGeneral Criteria for Somatic Mutation Genetic Testing ... initiate a related therapy and the therapy has been validated by the National Comprehensive Cancer Network™ (NCCN Guidelines™) as a category 1, 2A, or 2B recommendation for the ... Detection of circulating whole tumor cells for any other indication is considered experimental,
Bariatric Surgery and Procedures - Cigna
static.cigna.comThis Coverage Policy addresses bariatric surgery and procedures for the treatment of morbid obesity. Coverage Policy . Coverage for bariatric surgery or revision of a bariatric surgery procedure varies across plans and may be governed by state mandates. Refer to the customer’s benefit plan document for coverage details.
Anesthesia Services for Interventional Pain Management ...
static.cigna.comMonitored anesthesia care (MAC) is a service rendered by an anesthesia practitioner (i.e., anesthesiologist, certified registered nurse anesthetist CRNA]) who is not involved in the diagnostic or procedural service being performed. The ASA defines MAC as
REVENUE CODE LIST-CPT-HCPCS - Cigna
static.cigna.comREVENUE CODE LIST-CPT-HCPCS For Providers Effective March 15, 2020 . All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, includingCigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., and HMO or service
Minimally Invasive Spine Surgery Procedures and Trigger ...
static.cigna.comTrigger Point: Trigger point injection therapy involves the injection of anesthetic or corticosteroids into distinct, focal hyper-irritable spots (i.e., trigger points) located in a tight band of skeletal muscle. Myofascial pain syndrome is a chronic form of muscle pain centered near trigger points.
Diabetes Equipment and Supplies
static.cigna.com• hypoglycemic wristband alarm (e.g., Diabetes Sentry™) External Insulin Pumps . ANY of the following external insulin pumps * is considered medically necessary for the management of type 1 and type 2 diabetes mellitus: • an external insulin pump* (HCPCS code E0784) including a combined or integrated continuous
Welcome to Cigna Behavioral Health
static.cigna.comThe practitioner has thirty (30) days from the receipt of the suspension or termination letter to make a written request for reconsideration. Cigna Behavioral Health's Credentialing Committee Appeal Panel will review the appeal at its next monthly meeting and issue a written notification of the outcome to the practitioner.
Speech Therapy - Cigna
static.cigna.comspeech-language pathologist for a significant voice disorder associated with the laryngeal structures that are associated with anatomic abnormality, neurological condition, injury (e.g., vocal nodules or polyps, vocal cord paresis or paralysis, paradoxical vocal …
Transcranial Magnetic Stimulation
static.cigna.comTranscranial Magnetic Stimulation (TMS) for Depression . Transcranial magnetic stimulation (TMS) is a non-invasive neurostimulation technique that modulates cortical excitability. In repetitive TMS (rTMS), trains of several pulses are delivered through repeated stimulation over the same area with frequencies ranging from 1 to 20 Hz.
Orthotic Devices and Shoes - Cigna
static.cigna.comI. Cranial Orthosis Coding for Cranial Orthoses • A custom molded/fitted cranial orthotic device (HCPCS code S1040) is considered medically necessary for the treatment of synostotic plagiocephaly (i.e., craniosynostosis) following surgical correction when the benefit plan includes coverage for this indication.
Related documents
Official American Thoracic Society/Infectious Diseases ...
www.cdc.govinfection [LTBI]). TB disease is a leading cause of infectious disease morbidity and mortality worldwide, with many diag-nostic uncertainties. A task force supported by the supported by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America
Frequently Asked Questions: COVID-19 Testing at Skilled ...
www.cms.govtesting. In areas of high prevalence or for patients with known risk factors, positive results from an antigen test can be considered confirmatory and used for diagnostic purposes. In areas of high prevalence, confirming negative results using an alternate form of testing is recommended.
Genitourinary Pathogen Detection Panel Testing
www.uhcprovider.comInfectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for ... Molecular testing for diagnosis of vaginal infection is based on the detection of one or more specific nucleic acid sequences. In . ... small number of cases and therefore is an inconsistent diagnostic feature (Huppert, 2009).
INFECTIOUS DISEASES LABORATORY TEST DIRECTORY
www.cdc.govSpecimen Labeling This test order can accommodate diagnostic and non-diagnostic specimens. Testing subject to CLIA regulations requires two primary patient identifiers (e.g., patient first and last name, date of birth, unique patient identifier from time of collection, such as medical record number) on the specimen container and on the